Top 10 Best Pharmaceutical Companies In UAE 2026

Our ranking of the top pharmaceutical companies in the UAE for 2026 weighs global revenue figures, regional market presence, and strategic importance to the country's healthcare goals. We examined 2025 financial reports from each company, their registered product portfolios in the Emirates, and their investments in local manufacturing and research partnerships. Companies with growing revenue and a documented commitment to the UAE market ranked higher. Domestic manufacturers received consideration for their role in the UAE's push to reduce import dependency, though global scale still factored heavily into the final order.

The List Of Top 10 Best Pharmaceutical Companies In UAE 2026:

1. Johnson & Johnson

Johnson & Johnson sits at the top of our list, and it isn't close. The company generated $94.2 billion in global revenue in 2025, making it the largest pharmaceutical company in the world by that measure. In the UAE, its Innovative Medicine division supplies a substantial share of patented drugs, particularly in immunology and oncology.

The blockbuster drug Darzalex, used in multiple myeloma treatment, anchors a portfolio that hospitals across the Emirates rely on. What sets Johnson & Johnson apart in this market is its diversified business model. The company's medical devices and consumer health divisions give it relationships with UAE healthcare providers that pure-play pharma companies simply don't have. That breadth translates into distribution muscle and institutional trust.

For a country investing heavily in specialized care, Johnson & Johnson's oncology pipeline matters. The UAE's cancer treatment centers, including those in Abu Dhabi's healthcare free zones, stock its therapies as first-line options. Its scale means it can absorb pricing pressure and regulatory changes better than smaller competitors.

2. Eli Lilly and Company

Eli Lilly is the fastest-growing major pharmaceutical company in the world, and that momentum is reshaping diabetes and obesity care in the UAE. The company posted $65.2 billion in global revenue in 2025, a staggering 44.7% year-over-year increase. The metabolic drugs Mounjaro and Zepbound now account for 56% of its revenue.

That growth matters in the UAE because the country has one of the highest rates of type 2 diabetes in the world. According to the International Diabetes Federation, roughly one in five adults in the UAE lives with diabetes. Lilly's GLP-1 medications have become standard prescriptions in clinics from Dubai to Al Ain, and demand shows no signs of slowing.

Industry analysts project Lilly could overtake Johnson & Johnson as the world's largest pharma company by 2027 or 2028. If that trajectory holds, its influence in the UAE will only deepen. The company is also investing in manufacturing capacity globally, which could eventually include regional supply chains that benefit the Emirates.

3. AstraZeneca

AstraZeneca brings a different strength to the UAE: a focus on the chronic diseases that dominate the country's healthcare spending. The company generated $58.7 billion in global revenue in 2025, up 8% year over year. Its therapeutic focus covers oncology, cardiovascular disease, and respiratory conditions, all of which are significant health burdens in the Gulf region.

Tagrisso, a lung cancer treatment, and Enhertu, an antibody-drug conjugate, drive much of the company's growth. AstraZeneca has set a target of $80 billion in annual revenue by 2030, and its pipeline supports that ambition.

What makes AstraZeneca particularly relevant to the UAE is its investment in local research and digital health initiatives. The company has partnered with UAE health authorities on data-driven approaches to chronic disease management. As the Emirates positions itself as a hub for medical innovation, those partnerships carry weight beyond simple drug sales.

4. Pfizer

Pfizer remains a dominant supplier to the UAE's Ministry of Health and private hospital networks, even as its overall revenue dipped slightly in 2025. The company posted $62.6 billion in global revenue, a modest decline from the COVID-era peaks that inflated its numbers. The products driving its current performance are Eliquis, an anticoagulant, and Vyndaqel, a treatment for a rare heart condition.

Pfizer's legacy in the UAE runs deep. The company has been present in the region for decades, and its vaccine portfolio is deeply embedded in the country's immunization programs. When the UAE launched one of the world's fastest COVID-19 vaccination campaigns in 2020 and 2021, Pfizer's mRNA vaccine was a cornerstone of that effort.

The company's broad distribution network is its moat. Hospitals, pharmacies, and government procurement channels in the UAE are familiar with Pfizer's logistics and quality standards. That operational reliability keeps it among the top suppliers in the country, even without blockbuster growth.

5. Roche

Roche occupies a unique position in the UAE because it operates in both pharmaceuticals and diagnostics. The Swiss company generated CHF 61.5 billion in global revenue in 2025, with its pharma division driven by Vabysmo, an eye disease treatment, and Hemlibra, a hemophilia therapy. Its diagnostics arm supplies laboratory equipment and testing systems to hospitals across the Emirates.

That dual focus creates advantages that pure pharma companies can't replicate. When a UAE hospital runs diagnostic tests that identify a specific genetic marker, Roche's pharmaceutical division often has a targeted therapy to match. This integrated approach aligns with the UAE's push toward precision medicine, particularly in oncology.

Abu Dhabi's healthcare authorities have prioritized personalized medicine as part of their long-term strategy. Roche's ability to connect diagnostics with treatment makes it a strategic partner in that effort, not just a drug supplier.

6. Novartis

Novartis brings a deep portfolio in oncology, immunology, and neuroscience to the UAE market. The Swiss company posted $54.5 billion in global revenue in 2025. Its two biggest sellers, Cosentyx and Entresto, are well-established in the region. Cosentyx treats autoimmune conditions like psoriasis and arthritis, while Entresto addresses heart failure.

The company has spent recent years simplifying its portfolio, shedding non-core businesses to focus on high-growth therapeutic areas. That strategic discipline has made it a resilient player in markets like the UAE, where healthcare authorities increasingly demand evidence of value from drug manufacturers.

Novartis also has a strong presence in the UAE's clinical trial landscape. The country has been working to attract more clinical research, and Novartis's willingness to conduct studies in the region supports that ambition. For UAE patients, that means earlier access to investigational therapies.

7. Sanofi

Sanofi is the only company on this list with a significant local manufacturing presence in the UAE. The French pharmaceutical giant owns a majority stake in Globalpharma, one of the region's leading drug manufacturers. That makes Sanofi uniquely important to the UAE's stated goal of increasing domestic pharmaceutical production.

The company posted €43.6 billion in global revenue in 2025, up 9.9% year over year. Its growth is driven by Dupixent, a treatment for asthma and eczema, and Beyfortus, a respiratory syncytial virus antibody. Both drugs have strong uptake in the Gulf region.

The UAE currently imports about 80% of its pharmaceuticals. Government policy aims to change that. Sanofi's local operations put it at the center of that effort, giving the company a strategic foothold that pure importers can't match. When UAE authorities talk about pharmaceutical self-sufficiency, Sanofi is part of the conversation.

8. Julphar (Gulf Pharmaceutical Industries)

Julphar is the UAE's flagship homegrown pharmaceutical company and the largest manufacturer in the Middle East and Africa. While its revenue doesn't approach the global giants on this list, its strategic importance to the UAE exceeds its financial scale. The company produces more than 2,500 locally made medicines.

Julphar's role in the UAE's healthcare strategy cannot be overstated. The country imports roughly 80% of its pharmaceuticals, a dependency that government officials have identified as a vulnerability. Julphar is central to the plan to reduce that figure, with the UAE's pharmaceutical manufacturing sector operating 23 production centers nationwide.

The company has faced challenges in recent years, including quality-control issues that led to regulatory penalties in some export markets. But its position as the leading domestic producer secures its place on this list. No other company is as tied to the UAE's industrial policy as Julphar.

9. AbbVie

AbbVie has successfully navigated one of the most difficult transitions in modern pharma: replacing revenue from Humira, once the world's best-selling drug, with a new generation of therapies. The company posted $61.2 billion in global revenue in 2025, up 8.6% year over year.

The drugs carrying that growth are Skyrizi and Rinvoq, both immunology treatments that have filled the gap left by Humira's patent expiration. AbbVie has also invested heavily in oncology and neuroscience, diversifying beyond its historical reliance on a single blockbuster.

In the UAE, AbbVie is a key supplier of advanced therapies for autoimmune diseases. The country's growing population of patients with conditions like rheumatoid arthritis and inflammatory bowel disease has created steady demand for these treatments. AbbVie's pipeline suggests it will remain a major player in the UAE for years to come.

10. Novo Nordisk

Novo Nordisk closes our list, but its products are among the most visible in the UAE. The Danish company generated 309 billion Danish kroner, about $46.7 billion, in global revenue in 2025, up 6.4% year over year. It produces nearly half of the world's insulin.

The UAE's high diabetes prevalence makes Novo Nordisk's products essential. Ozempic and Wegovy, the company's GLP-1 medications, have seen massive demand across the Emirates, both for diabetes management and weight loss. The company's dominance in this therapeutic area makes it indispensable to UAE healthcare providers.

Competition in the GLP-1 space is intensifying, with Eli Lilly's Mounjaro and Zepbound gaining ground. But Novo Nordisk's history in diabetes care, its insulin production capacity, and its relationships with UAE endocrinologists give it a durable advantage. For a country where diabetes is a national health priority, Novo Nordisk is not going anywhere.

The companies on this list represent two distinct forces shaping the UAE's pharmaceutical market. Global giants like Johnson & Johnson, Eli Lilly, and Pfizer supply the patented drugs that drive cutting-edge care. Domestic players like Julphar anchor the country's push for manufacturing self-sufficiency. Sanofi, with its Globalpharma subsidiary, bridges both worlds.